MALAT-1 Is a Key Regulator of Epithelial-Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis

被引:7
|
作者
Hussein, Mohamed Ali [1 ,2 ]
Valinezhad, Kamyab [3 ]
Adel, Eman [2 ]
Munirathinam, Gnanasekar [3 ]
机构
[1] Childrens Canc Hosp Egypt, Dept Pharmaceut Serv, Cairo 57357, Egypt
[2] Amer Univ Cairo, Sch Sci & Engn, Dept Biol, New Cairo 11835, Egypt
[3] Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA
关键词
MALAT-1; EMT; metastasis; chemoresistance; microRNA; lncRNA; NONCODING RNA MALAT1; SQUAMOUS-CELL CARCINOMA; LNCRNA MALAT1; GASTRIC-CANCER; CISPLATIN RESISTANCE; CERVICAL-CANCER; RHO-GTPASES; HEPATOCELLULAR-CARCINOMA; LUNG ADENOCARCINOMA; SIGNALING PATHWAY;
D O I
10.3390/cancers16010234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is overexpressed in several cancers and exerts its effect by controlling gene expression and stimulating cell proliferation, migration, and metastasis and playing a dynamic role in mediating the epithelial-to-mesenchymal transition (EMT), which leads to the acquisition of stem cell-like properties and chemoresistance. MALAT-1 modulates EMT by interacting with various intracellular signaling pathways, including phosphoinositide 3-kinase (PI3K)/Akt and Wnt/beta-catenin. It also sponges microRNAs, consequently increasing the gene expression of several essential genes regulating cancer progression and metastasis, rendering it a good candidate for therapeutic intervention. Several innovative approaches have been exploited to target MALAT-1, such as short hairpin RNAs (shRNAs), antisense oligonucleotides (ASOs), and natural products.Abstract Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is a long intergenic non-coding RNA (lncRNA) located on chr11q13. It is overexpressed in several cancers and controls gene expression through chromatin modification, transcriptional regulation, and post-transcriptional regulation. Importantly, MALAT-1 stimulates cell proliferation, migration, and metastasis and serves a vital role in driving the epithelial-to-mesenchymal transition (EMT), subsequently acquiring cancer stem cell-like properties and developing drug resistance. MALAT-1 modulates EMT by interacting with various intracellular signaling pathways, notably the phosphoinositide 3-kinase (PI3K)/Akt and Wnt/beta-catenin pathways. It also behaves like a sponge for microRNAs, preventing their interaction with target genes and promoting EMT. In addition, we have used bioinformatics online tools to highlight the disparities in the expression of MALAT-1 between normal and cancer samples using data from The Cancer Genome Atlas (TCGA). Furthermore, the intricate interplay of MALAT-1 with several essential targets of cancer progression and metastasis renders it a good candidate for therapeutic interventions. Several innovative approaches have been exploited to target MALAT-1, such as short hairpin RNAs (shRNAs), antisense oligonucleotides (ASOs), and natural products. This review emphasizes the interplay between MALAT-1 and EMT in modulating cancer metastasis, stemness, and chemoresistance in different cancers.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] ZEB1 promotes epithelial-mesenchymal transition in cervical cancer metastasis
    Ran, Jing
    Lin, Dian-Liang
    Wu, Rong-Feng
    Chen, Qiong-Hua
    Huang, Hui-Ping
    Qiu, Na-Xuan
    Quan, Song
    FERTILITY AND STERILITY, 2015, 103 (06) : 1606 - 1618
  • [22] Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition
    Ying, Liang
    Chen, Qi
    Wang, Yawei
    Zhou, Zhihua
    Huang, Yiran
    Qiu, Feng
    MOLECULAR BIOSYSTEMS, 2012, 8 (09) : 2289 - 2294
  • [23] Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways
    Sabouni, Eisa
    Nejad, Melina Maghsodlou
    Mojtabavi, Sarah
    Khoshdooz, Sara
    Mojtabavi, Mahsa
    Nadafzadeh, Niloufar
    Nikpanjeh, Negin
    Mirzaei, Sepideh
    Hashemi, Mehrdad
    Aref, Amir Reza
    Khorrami, Ramin
    Nabavi, Noushin
    Ertas, Yavuz Nuri
    Salimimoghadam, Shokooh
    Zandieh, Mohammad Arad
    Rahmanian, Parham
    Taheriazam, Afshin
    Hushmandi, Kiavash
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 160
  • [24] Forkhead box C1 induces epithelial-mesenchymal transition and is a potential therapeutic target in nasopharyngeal carcinoma
    Lei Ou-Yang
    Xiao, Sheng-Jun
    Liu, Peng
    Yi, Shi-Jang
    Zhang, Xiao-Ling
    Shi Ou-Yang
    Tan, Sheng-Kui
    Lei, Xun
    MOLECULAR MEDICINE REPORTS, 2015, 12 (06) : 8003 - 8009
  • [25] DDR1 enhances invasion and metastasis of gastric cancer via epithelial-mesenchymal transition
    Xie, Ruixia
    Wang, Xiaoying
    Qi, Guoqing
    Wu, Zhiping
    Wei, Rong
    Li, Peirong
    Zhang, Dekui
    TUMOR BIOLOGY, 2016, 37 (09) : 12049 - 12059
  • [26] Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis
    Datta, Arpita
    Deng, Shuo
    Gopal, Vennila
    Yap, Kenneth Chun-Hong
    Halim, Clarissa Esmeralda
    Lye, Mun Leng
    Ong, Mei Shan
    Tan, Tuan Zea
    Sethi, Gautam
    Hooi, Shing Chuan
    Kumar, Alan Prem
    Yap, Celestial T.
    CANCERS, 2021, 13 (08)
  • [27] SATB1 promotes epithelial-mesenchymal transition and metastasis in prostate cancer
    Qi, Honggang
    Fu, Xinyang
    Li, Yeping
    Pang, Xiang
    Chen, Sansan
    Zhu, Xiaojun
    Li, Fei
    Tan, Wanlong
    ONCOLOGY LETTERS, 2017, 13 (04) : 2577 - 2582
  • [28] MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT)
    Ding, Xiang-Ming
    CHINESE JOURNAL OF CANCER, 2014, 33 (03) : 140 - 147
  • [29] Effects of fascin1 on epithelial-mesenchymal transition and metastasis of human gastric cancer cells
    Qiu, Hui
    Zhao, Rende
    Shi, Zhimeng
    Li, Lei
    Guo, Yanji
    Zhao, Wenxing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (04): : 4043 - 4049
  • [30] Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
    Shang, Yulong
    Cai, Xiqiang
    Fan, Daiming
    CURRENT CANCER DRUG TARGETS, 2013, 13 (09) : 915 - 929